Thierry Lecomte

Also affiliated with Inserm, Centre Hospitalier Universitaire de Tours

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer”.

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

JAMA Oncology(2022)10.1001/jamaoncol.2022.3829

N/A

9.5DataRank · unranked

335 citations

Florence Castan, Anthony Lopez, Anthony Turpin, Meher Ben Abdelghani, Alice C. Wei +87 more

LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

Annals of Oncology(2023)10.1016/j.annonc.2023.10.048

N/A

0DataRank · unranked

7 citations

Thierry Lecomte, Julien Hadoux, Patricia Niccoli, Léa Saban-Roche, E. Gaye +15 more